The Annual Meeting of the American Association for Cancer Research (AACR), a global event for basic and translational study on cancer, was grandly held in Orlando, Florida, USA from April 14 to April 19, 2023. The Annual Meeting is the 114th Annual Meeting of AACR. At the meeting, Suzhou Puhe Biopharma submitted two independently developed projects, PH009-1 (the fourth-generation EGFR project) and PH020-803 (a new generation PRMT5 inhibitor), to the AACR Annual Meeting. This is also the first time that the study data of Puhe Biopharma has been publicly disclosed, and both projects have been highly recognized by the Meeting committee. Where, PH009-1 was presented with posters at the Meeting, PH020-803 was invited to give an oral presentation at the meeting. Currently, both abstracts have been made public online.

On April 7, 2023, Suzhou Puhe Biopharma Science and Technology Co., Ltd. has achieved a notable milestone with the successful enrollment of the first patient in the Phase III clinical study of its self-developed Class 1 new drug, YK-029A. This pivotal study, conducted at the Union Hospital affiliated with Tongji Medical College of Huazhong University of Science and Technology, targets locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR Exon 20 insertion mutations, comparing YK-029A to first-line platinum-based doublet chemotherapy. Led by Professor Wang Jie from the Cancer Hospital of the Chinese Academy of Medical Sciences, this large-scale Phase III study involves collaboration across 60 centers nationwide.

Suzhou, China, February 10, 2023- Suzhou Puhe Biopharma announced today that its application for Phase III clinical trial for a small molecule innovative drug (PH001) in the field of lung cancer has been accepted and approved by the National Medical Products Administration for use in advanced NSCLC patients with EGFR Ex20ins who have not undergone systematic treatment.